The role of CD55 in protecting the tumour environment from complement attack

Tissue Antigens

Volumn 60, Issue 3, 2002, Pages 213-223

  Morgan, J ^a   Spendlove, I ^a   Durrant, Lindy G ^a,b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

CD55; Extracellular matrix; Matrix metalloproteinase 7; Tumour; Vascular endothelial growth factor

Indexed keywords

COLLAGENASE; COMPLEMENT; CYTOKINE; DECAY ACCELERATING FACTOR; MATRILYSIN; MATRIX METALLOPROTEINASE; PAPAIN; VASCULOTROPIN; COMPLEMENT COMPONENT C3B; ENDOTHELIAL CELL GROWTH FACTOR; LYMPHOKINE; SIGNAL PEPTIDE; VASCULOTROPIN A;

ANGIOGENESIS; ANTIGEN EXPRESSION; ARTICLE; CELL INVASION; CELL PROTECTION; CELL SURFACE; COMPLEMENT DEPOSITION; CONTROLLED STUDY; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; INFLAMMATION; PRIORITY JOURNAL; TUMOR CELL LINE; CELL CULTURE; COLORECTAL TUMOR; CYTOLOGY; DRUG EFFECT; IMMUNOLOGY; METABOLISM; OSTEOSARCOMA; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANTIGENS, CD55; COLORECTAL NEOPLASMS; COMPLEMENT C3B; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIUM, VASCULAR; EXTRACELLULAR MATRIX; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; MATRIX METALLOPROTEINASE 7; OSTEOSARCOMA; TUMOR CELLS, CULTURED; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0036760340     PISSN: 00012815     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0039.2002.600303.x     Document Type: Article

References (25)

1. Hindmarsh EJ, Marks RM. Decay-accelerating factor is a component of subendothelial extracellular matrix in vitro, and is augmented by activation of endothelial protein kinase C. Eur J Immunol 1998: 28: 1052-62.
2. Lidington EA, Haskard DO, Mason JC. Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood 2000: 96: 2784-92.
3. Mason JC, Yarwood H, Sugars K, Morgan BP, Davies KA, Haskard DO. Induction of Decay-accelerating factor by cytokines or the membrane-attack complex protects vascular endothelial cells against complement deposition. Blood 1999: 94: 1673-82.
4. Hindmarsh EJ, Marks RM. Complement activation occurs on subendothelial extracellular matrix in vitro and is initiated by retraction or removal or overlying endothelial cells. J Immunol 1998: 160: 6128-36.
5. Li L, Spendlove I, Morgan J, Durrant LG. CD55 is over-expressed in the tumour environment. Br J Cancer 2001: 84: 80-6.
6. Niehans GA, Cherwitz DL, Staley NA, Knapp DJ, Dalmasso AP. Human Carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin). Am J Pathol 1996: 149: 129-42.
7. Thorsteinsson L, Odowd GM, Harrington PM, Johnson PM. The complement regulatory proteins CD46 and CD59, but not CD55, are highly expressed by glandular epithelium of human breast and colorectal tumour tissues. Apmis 1998: 106: 869-78.
8. Yamakawa M, Yamada K, Tsuge T et al. Protection of thyroid-cancer cells by complement-regulatory factors. Cancer 1994: 73: 2808-17.
9. Unemori E, Ferrara N, Bauer E, Amento E. Vascular endothelial growth factor induces interstitial collagenase expression in human endothelial cells. J Cellular Physiol 1992: 153: 557-62.
10. Khira Y, Mori K, Miyazaki K, Muto Y. Production of recombinant human matrix metalloproteinase 7 (Matrilysin) with potential role in tumour invasion by refolding from Escherichia coli inclusion bodies and development of sandwich ELISA of MMP-7. Urol Oncol 1996: 2: 20-6.
11. Durrant LG, Robins RA, Ballantyne KC, Marksman RA, Hardcastle. JD, Baldwin RW. Enhanced recognition, of human colorectal tumour-cells using combinations of monoclonal-antibodies. Br J Cancer 1989: 60: 855-60.
12. Carrington CA, dos Santos Cruz G. Effect of cell surface concentration of human DAF on transgenic pig aortic endothelial cells on the degree of protection afforded against human complement deposition. Xenotransplantation 2001: 8: 100-5.
13. Tosello AC, Mary F. Activation of T cells via CD55: Recruitment of early components of the CD3-TCR pathway is required for IL-2 secretion. J Inflamm 1998: 48: 13-27.
14. Hamann J, Vogel B, Vanschijndel GMW, Vanlier RAW. The 7-span transmembrane receptor CD97 has a cellular ligand (CD55, DAF). J Exp Med 1996: 184: 1185-9.
15. Cozzi E, Bhatti F, Schmoeckel M et al. Long term survival of non human primates receiving life-supporting transgenic porcine kidneys. Transplantation 2000: 70: 15-20.
16. Gabrilovitch DI, Chen HL, Girgis KR et al. Production of vascular endothelium growth factor by human tumours inhibits the functional maturation of dendritic cells. Nature Med 1996: 10: 1096-103.
17. Liszewski MK, Farries TC, Lublin DM, Rooney IA, Atkinson JP. Control of the complement system. Adv Immunol 1996: 61: 201-83.
18. Medof ME, Walter EI, Rutger JL, Knowles DM, Nussenzweig V. Identification of the complement decay-accelerating factor (DAF) on the epithelium and glandular cells and in body fluids. J Exp Med 1987: 165: 848-64.
19. Moran P, Beasley H, Gorrell A et al. Human recombinant soluble decay accelerating factor inhibits complement activation in vitro and in vivo. J Immunol 1992: 149: 1736-43.
20. Jaffe EA, Nachman RL, Becker CG, Mindi CR. Culture of human endothelial cell derived from umbilical veins: Identification by morphological and immunological criteria. J Clin Invest 1972: 52: 2745-75.
21. Embleton MJ, Gunn B, Byers VS, Baldwin RW. Anti-tumour reactions of monoclonal antibody against a human osteogenic sarcoma cell line. Br J Cancer 1981: 43: 582-7.
22. Durrant LG, Denton GWL, Jacobs E et al. Anti-colorectal tumour cellular and humoral responses induced (in rats, mice and humans) by an idiotypic replica of carcino-embryonic antigen. Int J Cancer 1992: 50: 811-6.
23. Tate CG, Uchikawa M, Tanner MJA et al. Studies on the defect which causes absence of decay accelerating factor (DAF) from the peripheral blood cells of an individual with the inab phenotype. Biochem J 1989: 261: 489-93.
24. Spring FA, Judson PA, Daniels GL et al. A human glycoprotein that carries Cromer related blood group antigens on erythrocytes and is also expressed on leucocytes and platelets. Immunology 1987: 62: 307-12.
25. Coyne KE, Hall SE, Thompson S et al. Mapping of epitopes, glycosylation sites, and complement regulatory domains in human decay accelerating factor. J Immunol 1992: 149: 2906-13.